Time for Action: The Urgent Need for Immunization in Patients with IBD

Time for Action: The Urgent Need for Immunization in Patients with IBD

On-Demand Webcast
Chair

Millie D. Long, MD, MPH, FACG
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Faculty

Francis A. Farraye, MD, MSc, FACG
Boston Medical Center
Boston University School of Medicine
Boston, Massachusetts
 
Gil Y. Melmed, MD, MS, FACG
Cedars-Sinai Medical Center
Los Angeles, California

Target Audience

This activity is designed for gastroenterology physicians, internists, fellows, gastroenterology nurses, and related healthcare providers that are involved and/or interested in the therapeutic management of patients with IBD.

Overview

Patients with inflammatory bowel disease (IBD) face a number of health challenges, not the least of which is an increased risk of infection. However, many opportunistic infections to which patients with IBD are susceptible are preventable with currently available vaccinations. Guidelines recommend a number of immunizations that patients with IBD should receive as a precaution, especially at diagnosis and before beginning immunosuppressive treatment. This webcast from the Time for Action: The Urgent Need for Immunization in Patients with IBD symposium provides clinicians with expert guidance on ACG recommendations and guidelines pertaining to the need for vaccination in patients with IBD, and provides suggestions on how to implement these strategies for optimal clinical outcomes.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Outline vaccination recommendations for patients with IBD on low-level and high-level immunosuppression therapy, as per guidelines
  2. Ensure that every patient with IBD has had a review of immunization status and that all appropriate vaccinations are current
  3. Initiate a coordinated care practice with primary care clinicians for all patients with IBD to ensure vaccinations are up-to-date
  4. Provide education for all patients with IBD on the importance of immunization, including vaccine checklists that can be shared with primary care clinicians

Release Date: October 23, 2018

Expiration Date: October 23, 2019

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

Accreditation


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.

CNE

This continuing nursing education activity awards 1.50 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.50 contact hours.

CPE

This knowledge-based activity (JA0006201-9999-18-208-H01-P) is approved for 1.50 contact hours (0.015 CEUs) of continuing pharmacy education.

This educational activity is a knowledge-based activity.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period. (Deadline: December 8, 2018)

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Senior Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Senior Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Francis A. Farraye, MD, MSc, FACG, Millie D. Long, MD, MPH, FACG, Gil Melmed, MD, FACG; and Chris Bolwell, Monalisa Singh, and Susan Yarbrough, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

Francis A. Farraye, MD, MSc, FACG has received research and/or grant support from Celgene, has served as a consultant for Braintree, Ferring, Janssen, Lilly, Merck, Pfizer, Protagonist, Theravance, and Takeda, owns stock in Innovation Pharmaceuticals, and has received other support from Crohn’s and Colitis Foundation and Massachusetts Gastroenterology Association.

Millie D. Long, MD, MPH, FACG has received research and/or grant support from Pfizer and Takeda, and has served as a consultant for AbbVie, Janssen, Pfizer, Takeda, Targetpharmasolutions, Theravance, and UCB.

Gil Y. Melmed, MD, MS, FACG has received research and/or grant support from Pfizer, and has served as a consultant for AbbVie, Celgene, Janssen, Medtronic, Pfizer, Redhill Biopharma, Samsung Bioepis, and Takeda.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Monalisa Singh and Susan Yarbrough disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Disclosure of off-label/unapproved uses of drugs and/or devices will be provided prior to the symposium.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Support

This activity has been supported by an educational grant from Pfizer, Inc.